New immunotherapy trial aims to boost colon cancer surgery success
NCT ID NCT07412613
Summary
This study is testing if an immunotherapy drug called AK104, given before and after surgery, works better than standard chemotherapy for people with a specific type of colon cancer that can be surgically removed. It will involve about 386 adults with stage IIB-III colon cancer that tests positive for MSI-H or dMMR markers. The main goals are to see if the new treatment leads to no detectable cancer after surgery and prevents the cancer from coming back.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MSI-H/DMMR COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-sen University Cancer Center
Guangzhou, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.